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PROTEASOME INHIBITORS 
RELATED APPLICATIONS 
This application claims priority from U.S. Provisional 
Application Ser. No. 61/976,220 filed Apr. 7, 2014, the 
entire disclosure of which is incorporated herein by this 
reference. 
GOVERNMENT INTEREST 
This invention was made with govermnent support under 
R01 CA128903 awarded by National Institutes of Health. 
The government has certain rights in the invention. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to novel 
non-peptide proteasome inhibitors, their pharmaceutically 
acceptable salts, process(es) for their preparation, pharma-
ceutical compositions containing the novel non-peptide pro-
teasome inhibitors, and methods of treating disease(s) in a 
subject, including cancer, via administration of the non-
peptide proteasome inhibitors. 
INTRODUCTION 
The proteasome is a key player in one of the most 
fundamental processes in eukaryotic cells, the ubiquitin-
dependent protein degradation pathway. The proteasome is 
a large multi-subunit protease that degrades the majority of 
cellular proteins. The proteasome also controls critical cel-
lular process, such as the cell cycle, via the regulated 
degradation of signaling proteins. By perturbing these pro-
cesses, inhibition of the proteasome leads to apoptosis, 
especially in cancer cells. It is for this reason that pro tea-
some inhibitors have become critically important therapies 
in the treatment of multiple myeloma. 
The barrel-shaped 20S core of the proteasome consists of 
four stacked heptameric rings: two outer a-rings and two 
inner ~-rings (FIG. lA). While the two outer a-rings serve 
mainly structural roles, the two inner ~-rings have three 
catalytic subunits in each ring. In marmnalian cells, there 
exist two main proteasome subtypes: the constitutive pro-
teasome (CP) and the irmnunoproteasome (IP). These two 
proteasome subtypes differ by the incorporation of two 
distinct sets of catalytic subunits. The CP contains the 
catalytic subunits ~1, ~2, and ~5, which cleave peptide 
bonds after acidic (Caspase-Like, C-L), basic (Trypsin-Like, 
T-L) and hydrophobic (Chymotrypsin-Like, CT-L) residues, 
respectively. (2) The CP is expressed in all eukaryotic cells 
and plays key roles in many important intracellular pro-
cesses, such as cell cycle progression, development, and 
inflarmnation. On the other hand, the immunoproteasome is 
expressed in irmnune cells and can be induced in other cell 
types upon exposure to inflarmnatory cytokines, such as 
interferon-y (INF-y) and tumor necrosis factor-alpha (TNF-
a). (3) 
The 20S irmnunoproteasome core is structurally identical 
to the constitutive proteasome except for the incorporation 
of catalytic subunits ~1i, ~2i, and ~5i instead of ~1, ~2, and 
~5, respectively (FIG. lB). The catalytic activities of the 
immunoproteasome subunits ~2i and ~5i are relatively simi-
2 
Although the distinct catalytic subunits of the different 
proteasome isoforms have been suggested to play roles in 
adding antigenic diversity to peptides generated from pro-
tein degradation, the catalytic subunits responsible for the 
CT-L activity (~5 and 1350 are thought to be most physi-
ologically important and have been recognized as the key 
targets of bortezomib and carfilzomib. 
Due to the crucial roles of proteasomes in rapidly prolif-
erating cells such as cancer cells, the proteasome has been 
10 
exploited as a cancer target, resulting in bortezomib (Vel-
cade®), the first-in-class proteasome inhibitor approved by 
the FDA in 2003 for the treatment of relapsed multiple 
myeloma (MM). In 2012, a second-generation proteasome 
inhibitor carfilzomib was approved by the FDA for the 
treatment of relapsed multiple myeloma patients who have 
15 received at least two prior therapies, including bortezomib. 
The addition of these proteasome inhibitors to chemothera-
peutic armaments has dramatically improved the therapeutic 
landscape for patients with multiple myeloma (MM). 
Despite the remarkable successes of these drugs in the clinic, 
20 intrinsic and acquired drug resistance remains a major 
clinical challenge. Additionally, these drugs have failed to 
provide clinical benefit to patients with solid cancers, further 
adding to the need for next generation proteasome inhibi-
tors. 
25 Proteasome inhibitors are drugs designed to block and/or 
inhibit the ability of cancer cells to use certain proteins to 
carry out the cell cycle. When they are unable to complete 
this process, the result is the death of the cell. Currently, just 
a few proteasome inhibitors are available on the market, but 
30 
they are in wide use. They are: Velcade® and Kyprolis®. 
VELCADE® (bortezomib) is a targeted treatment, mean-
ing it does not kill cells indiscriminately but rather has a 
molecular target it seeks out. VELCADE® is FDA approved 
to treat multiple myeloma (a type of bone marrow cancer) as 
well as patients with mantle cell lymphoma who have failed 
35 first-line therapy. 
KYPROLIS® ( carfilzomib) is the second generation pro-
teasome inhibitor approved by the FDA in 2012 for the 
treatment of patients with relapsed/refractory multiple 
myeloma who have received at least two prior therapies 
40 including bortezomib. Phase II clinical trials found that its 
response rate is just under 25% with median duration of 
response of 7.8 months and overall survival of -16 months. 
Compared to VELCADE®, KYPROLIS® is shown to be a 
more selective proteasome inhibitor with reduced off target 
45 side effects such as peripheral neuropathy. 
In the last decade, the FDA approvals of the proteasome 
inhibitors bortezomib and carfilzomib have greatly 
improved the therapeutic landscape for patients with mul-
tiple myeloma. Indeed, these FDA approvals have validated 
50 the proteasome as an important target in the treatment of 
multiple myeloma. Despite these exciting advancements, 
there is still much work to be done to provide inhibitors 
which overcome intrinsic and acquired drug resistance, 
which have clinical utility outside of multiple myeloma, and 
55 which have improved pharmacokinetic properties. 
Accordingly, the subject matter of the present disclosure 
relates to the development of novel proteasome inhibitors 
and that have improved pharmacokinetic properties and 
broader and/or unique treatment applications as compared to 
60 compounds known in the art. 
SUMMARY 
lar to that of their constitutive proteasome counterparts, 
possessing T-L and CT-L activity, respectively. In contrast, 65 
the replacement of ~1 with ~1i results in a more significant 
change in the cleavage specificity from C-L to CT-L. 
The presently-disclosed subject matter meets some or all 
of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
US 9,493,439 Bl 
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This Summary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
Summary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative fea- 5 
tures of a given embodiment is likewise exemplary. Such an 
embodiment can typically exist with or without the 
feature(s) mentioned; likewise, those features can be applied 
to other embodiments of the presently-disclosed subject 
matter, whether listed in this Summary or not. To avoid 10 
excessive repetition, this Summary does not list or suggest 
all possible combinations of such features. 
The present disclosure includes non-peptide proteasome 
inhibitor, including a compound of formula (I), a pharma-
ceutically acceptable salt, solvate, or physiologically func- 15 
tiona! derivative thereof: 
(I) 
20 
25 
~ ~ 
R1 N/N 
" (CH2)n I 30 
R2 
In some embodiments of the compound of formula (I), R1 
is selected from 
35 
() CY· () N 40 H 
c'U y I . # 
45 
/N'-...._ 
CO-· CU· 50 I 
CY 55 H;COX! 
OAt/H I . 
H3CO # 
D 60 OCH3 H;N Cr 
"'"'''''" ' 
65 
4 
-continued 
and 
In some embodiments, R2 is selected from 
yo, yo yo HN 
H;C+CH; N OH H3C/ -...._CH3 
CH3 yo yo yo 
~2) ~lNl ~,("' CH3 
OH ~0 
yo yo 
~\ /N OD I# OY:J· I 
yo yo yo OQ H;C0 olym, 
S, 
Nd 
CH3 
CH3 yo yo yo 
~N 0 (xCH; , 
H3C OH 
5 
-continued 
In some emb d' 0 1ments R · ' 3 IS selected fi rom 
0 II o ll(~· 
0 CF3 
II 
-s !l? 
Cl 
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10 0 
II 
15 
-s ~y( 
F 
20 
25 ~0 H, 
30 
and 
35 
40 In some emb d' 0 1ments · 
In certain emb d' 'n IS 0, 1, or 2. 
R · 0 1ments f h 
1 IS selected from o t e compound 
of formula (I), 
US 9,493,439 Bl 
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In some emb d. 0 1ments R · ' 2 IS selected fi rom 
8 
10 
and n is 0 or 1 
In some emb. d. 
15 accordance wit~ tlments, the compound he following fi of formula (I) . . ormula(ae): ISm 
7 
and 
HN 
'cNH; 20 
and n is 0 or 1 
I . 
n some emb d. 0 1ments R · o ' 3 IS selected from 
i1( ~· ~· 25 30 
In some emb d. CF3 
e compound f 0 formula (I), R 1s 0 lments ofth yo 'eo 
HN 
''''··cNH; 
and n is 0 or 1. 
In some emb . odlments R . 3 IS 
0 
II 
--s ~y 
40 
45 
50 
I CF3 
nsomeemb d. is 0 lments ofth e compound f 0 formula (I) R ' 3 55 
60 
65 
H3CO 
H3CO 
OCH3 
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9 
-continued 
H3C 
~ ~ 
N/N 
l_( 
0 
/j 0/y 
CF3 
""(]NH 
H3C 
10 
15 
20 
35 
40 
10 
-continued 
or 
D 
The presently-disclosed subject matter further includes a 
pharmaceutical composition, which includes at least one 
compound according to formula (I) and a pharmaceutically-
acceptable carrier. 
The presently-disclosed subject matter also includes a 
method of inhibiting a proteasome in a cell, which involves 
administering or contacting the compound of formula (I) to 
the cell. The administrating or contacting the compound to 
the cell can lead to apoptosis of the cell. The cell can be, for 
45 example, a cancer cell. 
The presently-disclosed subject matter also includes a 
method of treating a disease in a subject, which includes 
administering an effective amount of a pharmaceutical com-
position containing the compound of formula (I) to the 
50 subject. The disease can be, for example, a cancer. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The novel features of the invention are set forth with 
55 particularity in the appended claims. A better understanding 
of the features and advantages of the present invention will 
be obtained by reference to the following detailed descrip-
tion that sets forth illustrative embodiments, in which the 
principles of the invention are used, and the accompanying 
60 drawings of which: 
FIG. lA illustrates the 26S proteasome, which is com-
posed of a 20S core and 19S regulatory complex. FIG. lB 
presents a schematic representation of subunit composition 
within a 20S proteasome core. Each ~-ring contains three 
65 catalytic subunits. FIG. lC provides the chemical structure 
of two FDA-approved proteasome inhibitors, bortezomib 
(Velcade®) and carfilzomib (Kyprolis®). 
US 9,493,439 Bl 
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FIG. 2A shows the step-wise screening process employed 
to identifY non-peptide proteasome inhibitors of the present 
disclosure. FIG. 2B provides a synthetic scheme ofG4. FIG. 
2C illustrates properties of G4, one of the compounds that 
selectively inhibits subunits responsible for the CT-L and 
C-L activities (~5, ~5i, ~1 and ~li), but not for the T-L 
activity (~2i) Purified 20S immunoproteasome and consti-
tutive proteasome were used. FIG. 2D shows that G4 
induces cancer cell death in lung cancer cell lines with IC50 
values of -7 f.LM. 10 
FIG. 3A illustrates structural features of G4 that are 
suitable for modification. FIG. 3B provides G4 derivatives, 
illustrating modifications relative to FIG. 3A. FIG. 3C 
depicts additional G4 derivatives. FIG. 3D illustrates inhibi- 15 
tory activity of selected G4 derivatives toward the CT-L 
activity of the proteasome. FIG. 3E provides screening 
results of G4 analogs against the CT-L activity of purified 
constitutive proteasome. FIG. 3F illustrates the cytotoxicity 
12 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. In case of conflict, the specification of 
this document, including definitions, will control. 
While the terms used herein are believed to be well 
understood by those of ordinary skill in the art, certain 
definitions are set forth to facilitate explanation of the 
presently-disclosed subject matter. Unless defined other-
wise, all technical and scientific terms used herein have the 
same meaning as commonly understood by one of ordinary 
skill in the art to which the presently-disclosed subject 
matter belongs. 
of selected compounds in Pane-l cells. FIG. 3G illustrates 20 
the correlation between the inhibitory potency against the 
CT-L activity and cytotoxic effects of G4 analogs. FIG. 3H 
illustrates inhibitory activity of selected G4 derivatives 
against more clinically relevant proteasome catalytic subunit 
Although any methods, devices, and materials similar or 
equivalent to those described herein can be used in the 
25 practice or testing of the presently-disclosed subject matter, 
representative methods, devices, and materials are now 
described. 
X. 
FIGS. 4A and 4B illustrate the predicted 05 binding mode 
of G4-1 and bortezomib generated by Autodock Vina.39 
Unless otherwise indicated, the term "administering" is 
inclusive of all means known to those of ordinary skill in the 
art for providing a preparation to a subject, including admin-
istration by inhalation, nasal administration, topical admin-
istration, intravaginal administration, ophthalmic adminis-
tration, intraaural administration, intracerebral 
administration, intravitreous administration, intracameral 
administration, posterior sub-Tenon administration, poste-
rior juxtascleral administration, subretinal administration, 
suprachoroidal administration, cell-based administration or 
production, rectal administration, and parenteral administra-
tion, including injectable such as intravenous administra-
FIG. SA shows that G4-1 is effective in inhibiting CT-L 
and C-L activities of proteasomes in RPMI 8226 cell 
extracts. The inhibitory effects ofG4-1 on the CT-L, C-L and 30 
T-L activities were measured by assessing the hydrolysis of 
the fluorogenic proteasome substrates Suc-LLVY-AMC, 
Z-LLE-AMC and Boc-LRR-AMC, respectively. FIG. SB 
demonstrates that as compared to carfilzomib (Cfz) and 35 
bortezomib (Btz), compound G4-1 has excellent metabolic 
stability when tested using liver microsomes prepared from 
Balb/c mice and BD UltraPooJT" human liver microsomes. 
FIG. SC provides a reaction progress curve with 30 min 
preincubation of RPMI 8226 cell extracts and G4-1. The 
upward curvature demonstrates that the proteasome was 
recovering and that the reaction was reversible. FIG. SD 
shows that G4-1 effectively induced cell death in multiple 
cancer cell lines. FIG. SE includes the potency of G4-1 in 
inducing cell death in BxPC-3 cell lines with acquired 
resistance to bortezomib or carfilzomib. FIG. SF provides a 
comparison of IC50 values of BxPC-3 sublines resistant to 
carfilzomib or bortezomib to its parental cell lines. 
40 tion, intra-arterial administration, intramuscular administra-
tion, and/or subcutaneous administration. Administration 
can be continuous or intermittent. A preparation can be 
administered therapeutically; that is, administered to treat an 
existing condition of interest. A preparation can be admin-
45 istered prophylactically; that is, administered for prevention 
of a condition of interest. 
In some embodiments a subject will be administered an 
effective amount of at least one compound provided in the 
present disclosure. In this respect, the term "effective 
50 amount" refers to an amount that is sufficient to achieve the 
FIG. 6 demonstrates that G4-1 inhibits tumor growth in 
vivo. Male nude mice bearing LNCaP tumors received 
intraperitoneal injections of either G4-1 (5 mg/kg), carfil-
zomib (5 mg/kg), or vehicle alone (8% DMSO in HP-~­
cyclodextrin and sodium citrate) twice a week for 4 weeks 
(n=5 mice/group). Results are expressed as mean and stan-
dard deviation. FIG. 6A presents tumor growth curves in 55 
animals receiving the respective treatments (*, p<O.OOl, 
significantly different from the control group, two-way 
ANOVAfollowed by Bonferroni post tests). FIG. 6B & FIG. 
6C provide average weights and images of tumors isolated 
at the end of the experimental period (*, p<O.OOl, signifi- 60 
cantly different from the control group, one-way ANOVA 
followed by Newman-Keuls post tests). FIG. 6D shows 
average body weights of mice receiving the respective 
treatments (#, p<O.Ol, significantly different from both G4-1 
and control groups, two-way ANOVA followed by Bonfer- 65 
rani post tests). FIG. 6E includes representative images of 
mice at the end of the experimental period. 
desired result or to have an effect on an undesired condition. 
For example, a "therapeutically effective amount" refers to 
an amount that is sufficient to achieve the desired therapeutic 
result or to have an effect on undesired symptoms, but is 
generally insufficient to cause adverse side effects. The 
specific therapeutically effective dose level for any particu-
lar patient will depend upon a variety of factors including the 
disorder being treated and the severity of the disorder; the 
specific composition employed; the age, body weight, gen-
eral health, sex and diet of the patient; the time of admin-
istration; the route of administration; the rate of excretion of 
the specific compound employed; the duration of the treat-
ment; drugs used in combination or coincidental with the 
specific compound employed and like factors well known in 
the medical arts. For example, it is well within the skill of 
the art to start doses of a compound at levels lower than 
those required to achieve the desired therapeutic effect and 
US 9,493,439 Bl 
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to gradually increase the dosage until the desired effect is 
achieved. If desired, the effective daily dose can be divided 
into multiple doses for purposes of administration. Conse-
quently, single dose compositions can contain such amounts 
or submultiples thereof to make up the daily dose. The 
dosage can be adjusted by the individual physician in the 
event of any contraindications. Dosage can vary, and can be 
administered in one or more dose administrations daily, for 
one or several days. Guidance can be found in the literature 
for appropriate dosages for given classes of pharmaceutical 10 
products. In further various aspects, a preparation can be 
administered in a "prophylactically effective amount"; that 
is, an amount effective for prevention of a disease or 
condition. 
Additionally, the terms "subject" or "subject in need 15 
thereof' refer to a target of administration, which optionally 
displays symptoms related to a particular disease, pathologi-
cal condition, disorder, or the like. The subject of the herein 
disclosed methods can be a vertebrate, such as a mammal, a 
fish, a bird, a reptile, or an amphibian. Thus, the subject of 20 
the herein disclosed methods can be a human, non-human 
primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea 
pig or rodent. The term does not denote a particular age or 
sex. Thus, adult and newborn subjects, as well as fetuses, 
whether male or female, are intended to be covered. A 25 
patient refers to a subject afflicted with a disease or disorder. 
The term "subject" includes human and veterinary subjects. 
The term "physiologically functional derivative" means 
any pharmaceutically acceptable derivative of a compound 
of the present disclosure. For example, an amide or ester of 30 
a compound of formula (I), which upon administration to a 
subject, particularly a mmal, is capable of providing, 
either directly or indirectly, a compound of the present 
disclosure of an active metabolite thereof. 
As will be recognized by one of ordinary skill in the art, 35 
the terms "suppression," "suppressing," "suppressor," "inhi-
bition," "inhibiting" or "inhibitor" do not refer to a complete 
elimination of angiogenesis in all cases. Rather, the skilled 
artisan will understand that the term "suppressing" or 
"inhibiting" refers to a reduction or decrease in angiogen- 40 
esis. Such reduction or decrease can be determined relative 
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sarcoma, chondrosarcoma, adenoma, breast cancer, prostate 
cancer, Kaposi's sarcoma and ovarian cancer, or metastases 
thereof. 
A subject may also be in need thereof because they have 
acquired diseases or conditions associated with abnormal 
and increased cell survival such as, but are not limited to, 
progression and/or metastases of malignancies and related 
disorders such as leukemia (including acute leukemias (e.g., 
acute lymphocytic leukemia, acute myelocytic leukemia, 
including myeloblastic, promyelocytic, myelomonocytic, 
monocytic, and erythroleukemia) and chronic leukemias 
(e.g., chronic myelocytic (granulocytic) leukemia and 
chronic lymphocytic leukemia)), polycythemia vera, lym-
phomas (e.g., Hodgkin's disease and non-Hodgkin's dis-
ease), multiple myeloma, Waldenstrom's macroglobuline-
mia, heavy chain disease, and solid tumors including, but not 
limited to, sarcomas and carcinomas such as fibrosarcoma, 
myxosarcoma, liposarcoma, chondrosarcoma, osteogenic 
sarcoma, chordoma, angiosarcoma, endotheliosarcoma, 
lymphangiosarcoma, lymphangioendotheliosarcoma, syn-
ovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, 
rhabdomyosarcoma, colon carcinoma, pancreatic cancer, 
breast cancer, ovarian cancer, prostate cancer, squamous cell 
carcinoma, basal cell carcinoma, adenocarcinoma, sweat 
gland carcinoma, sebaceous gland carcinoma, papillary car-
cinoma, papillary adenocarcinomas, cystadenocarcinoma, 
medullary carcinoma, bronchogenic carcinoma, renal cell 
carcinoma, hepatoma, bile duct carcinoma, choriocarci-
noma, seminoma, embryonal carcinoma, Wilm's tumor, 
cervical cancer, testicular tumor, lung carcinoma, small cell 
lung carcinoma, bladder carcinoma, epithelial carcinoma, 
glioma, astrocytoma, medulloblastoma, craniopharyngioma, 
ependymoma, pinealoma, hemangioblastoma, acoustic neu-
roma, oligodendroglioma, menangioma, melanoma, neuro-
blastoma, and/or retinoblastoma. The conditions, diseases, 
and the like described above, as well as those that will be 
apparent to those of ordinary skill in the art, are collectively 
referred to as "cancer" herein. 
As used herein, the terms "treatment" or "treating" relate 
to any treatment of a condition of interest, including but not 
limited to prophylactic treatment and therapeutic treatment. 
As such, the terms treatment or treating include, but are not 
limited to: preventing a condition of interest or the devel-
opment of a condition of interest; inhibiting the progression 
to a control. In some embodiments, the reduction or decrease 
relative to a control can be about a 1, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 
26,27, 28,29,30, 31, 32,33,34, 35,36,37,38, 39,40,41, 
42,43, 44,45,46, 47, 48,49, 50, 51, 52, 53, 54, 55, 56, 57, 
58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 
74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% decrease. 
45 of a condition of interest; arresting or preventing the devel-
opment of a condition of interest; reducing the severity of a 
condition of interest; ameliorating or relieving symptoms 
associated with a condition of interest; and causing a regres-
sion of the condition of interest or one or more of the 
In some embodiments the subject in need thereof will be 
suffering or will have been diagnosed with one or more 
neoplastic or hyperproliferative diseases, disorders, patholo-
gies, or conditions. Examples of such diseases, conditions, 
and the like include, but are not limited to, neoplasms 
(cancers or tumors) located in the colon, abdomen, bone, 
breast, digestive system, esophagus, liver, pancreas, perito-
neum, endocrine glands (adrenal, parathyroid, pituitary, tes-
ticles, ovaries, cervix, thymus, thyroid), eye, head and neck, 
nervous (central and peripheral), lymphatic system, pelvis, 
skin, soft tissue, spleen, thoracic areas, bladder, and uro-
genital system. Other cancers include follicular lymphomas, 
carcinomas with p53 mutations, and hormone-dependent 
tumors, including, but not limited to colon cancer, cardiac 
tumors, pancreatic cancer, melanoma, retinoblastoma, glio-
blastoma, lung cancer, intestinal cancer, testicular cancer, 
stomach cancer, neuroblastoma, myxoma, myoma, lym-
phoma, endothelioma, osteoblastoma, osteoclastoma, osteo-
50 symptoms associated with the condition of interest. 
Moreover, the subject matter of the present disclosure 
relates to the development of novel proteasome inhibitors 
that utilize a non-peptide scaffold. Indeed, the proteasome 
inhibitors of the present disclosure avoid the use of peptide 
55 backbone(s) and/or reactive pharmacophores. In some 
embodiments, the non-peptide inhibitors of the present 
disclosure comprise a substituted pyrazole scaffold, which 
provides for relatively potent inhibition of proteasome activ-
ity without relying on a peptide-based structure of a reactive 
60 pharmacophore. In some embodiments, the subject matter of 
the present disclosure is directed to reversible, non-peptide, 
non-covalent inhibitors of the 20S proteasome. The protea-
some inhibitors of the present disclosure have improved 
pharmacokinetic properties and broader treatment applica-
65 tions than those previously known in the art. In some 
embodiments, the non-peptide proteasome inhibitors of the 
present disclosure demonstrate activity against multiple 
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solid cancer cell lines, including cell lines with acquired 
resistance to bortezomib and/or carfilzomib. 
The FDA approval of the peptide-based proteasome 
inhibitors bortezomib and carfilzomib in 2003 and 2012, 
respectively, has validated the proteasome as an important 
target in the treatment of multiple myeloma. Additionally, 
these inhibitors have demonstrated in vitro as well moderate 
16 
(I) 
in vivo efficacy in preclinical models of solid tumors. 
Despite this, clinical trials utilizing these drugs for the 
treatment of solid tumors have shown disappointing results. 10 
Although the reasons for these failures remain unclear, one 
possibility is that existing proteasome inhibitors such as 
bortezomib and carfilzomib lack the pharmacokinetic and 
pharmacodynamics properties needed to sufficiently inhibit 
proteasomes in solid tumors. 15 In certain embodiments of the non-peptide proteasome inhibitor of formula I, R1 is chosen from: Proteasome inhibitors approved by the FDA are currently 
used for the treatment of multiple myeloma and mantle cell 
lymphoma. Despite strong indications of activity in preclini-
cal models, proteasome inhibitors in the clinic have failed to 
provide clinical benefits for solid cancer patients, presum-
ably due to poor metabolic stability. Research indicates that 
this is due to structural and functional properties of these 
inhibitors which are shared Pl 'sin clinical development-the 
reliance on a peptide backbone coupled with an electrophilic 
warhead to mediate covalent binding to the proteasome. It is 
believed that it is the structural and functional properties of 
known proteasome inhibitors which explain the high failure 
rate of those proteasome inhibitors in patients with solid 
tumors. (20, 36) 
With this in mind, it has been postulated that reversible, 
non-peptide proteasome inhibitors could be developed with 
improved properties and that these inhibitors could serve 
both as novel tools to advance the understanding of the 
proteasome and as potential therapeutic options for the 
treatment of solid tumors. 
In order to identifY novel proteasome inhibitors with 
non-peptide scaffolds, the present inventor(s) conducted an 
in silica screen of more than 340,000 structures followed by 
in vitro assays using purified proteasomes. This screening 
effort lead to several novel non-peptide compounds of 
interest. 
One such compound, a substituted pyrazole derivative, 
was used to synthesize a small library of analogues. The 
analogue compounds were evaluated for their ability to 
inhibit proteasome catalytic activity using specific fluoro-
genic substrates, and a structure-activity relationship was 
developed. In vitro cell viability assays were conducted 
against non-small cell lung cancer (NSCLC), pancreatic, 
prostate and multiple myeloma cell lines. The in vivo 
antitumor activity of the most promising analogue was also 
determined using a prostate cancer xenograph model. 
Moreover, the substituted pyrazole derivative was found 
to have reversible inhibitory activity against the chy-
motrypsin-like subunits of the 20S constitutive proteasome 
and immunoproteasome with single-micromolar IC50 val-
ues. It was equipotent against a series of cancer cell lines 
including bortezomib-resistant and carfilozmib-resistant 
cancer cell lines, despite varied sensitivity to bortezomib 
and carfilzomib. IC50 values against these cell lines were less 
than 10 f.LM. Using the analogue with improved potency and 
promising drug-like properties, inhibition of in vivo tumor 
growth was also observed. 
In some embodiments, the present disclosure provides a 
non-peptide proteasome inhibitor of formula (I), a pharma-
ceutically acceptable salt, solvate, or physiologically func-
tional derivative thereof: 
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In certain embodiments of the compound of formula I, R2 
is chosen from: 
and 
In some embodiments, n is 0 or 1. 
In certain embodiments of the compound of formula I, R3 
is chosen from: 
and 
In certain embodiments, R2 is 
and n is 0 or 1. 
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In certain embodiments, R3 is 
In certain embodiments, R2 is 
n is 0 or 1, and R3 is 
In some embodiments, the compound is according to the 
formula: 
H3CO 
H3CO 
OCH3 
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Certain compounds of formula (I) may exist in stereoi-
someric forms (e.g., they may contain one or more asym-
metric carbon atoms, or they may exhibit cis-trans isomer-
ism), and, the individual stereoisomers and mixtures of these 
55 are included within the scope of the present disclosure. 
The novel non-peptide proteasome inhibitors of the pres-
ent disclosure may be used for the treatment of a disease or 
condition, such as cancer. In some embodiments, there is 
provided a pharmaceutical composition for use in the treat-
60 ment (including prophylaxis) of one or more conditions or 
indications set forth herein, which comprises a compound of 
formula I, a pharmaceutically acceptable salt, solvate, or 
physiologically functional derivative thereof, and a pharma-
ceutically acceptable carrier or excipient. 
65 Processes for preparing a pharmaceutically acceptable 
salt, solvate and/or a physiologically functional derivative of 
the compound(s) of formula (I) are conventional in the art. 
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The presently-disclosed subject matter further includes 
pharmaceutical compositions of the compounds as disclosed 
herein, and further includes a pharmaceutically-acceptable 
carrier. In this regard, the term "pharmaceutically acceptable 
carrier" refers to sterile aqueous or non-aqueous solutions, 
dispersions, suspensions or emulsions, as well as sterile 
powders for reconstitution into sterile injectable solutions or 
dispersions just prior to use. Proper fluidity can be main-
26 
sodium starch glycollate); or wetting agents (e.g., sodium 
Iaury! sulphate). The tablets can be coated by methods 
known in the art. 
Liquid preparations for oral administration can take the 
form of, for example, solutions, syrups or suspensions, or 
they can be presented as a dry product for constitution with 
water or other suitable vehicle before use. Such liquid 
preparations can be prepared by conventional techniques 
tained, for example, by the use of coating materials such as 10 
with pharmaceutically acceptable additives such as suspend-
ing agents (e.g., sorbitol syrup, cellulose derivatives or 
hydrogenated edible fats); emulsifying agents (e.g. lecithin 
or acacia); non-aqueous vehicles (e.g., almond oil, oily 
esters, ethyl alcohol or fractionated vegetable oils); and 
lecithin, by the maintenance of the required particle size in 
the case of dispersions and by the use of surfactants. These 
compositions can also contain adjuvants such as preserva-
tives, wetting agents, emulsifying agents and dispersing 15 preservatives (e.g., methyl or propyl-p-hydroxybenzoates or 
sorbic acid). The preparations can also contain buffer salts, agents. Prevention of the action of microorganisms can be 
ensured by the inclusion of various antibacterial and anti-
fungal agents such as para ben, chlorobutanol, phenol, sorbic 
acid and the like. It can also be desirable to include isotonic 
flavoring, coloring and sweetening agents as appropriate. 
Preparations for oral administration can be suitably formu-
lated to give controlled release of the active compound. For 
20 
agents such as sugars, sodium chloride and the like. Pro-
buccal administration the compositions can take the form of 
tablets or lozenges formulated in conventional mauner. 
longed absorption of the injectable pharmaceutical form can 
be brought about by the inclusion of agents, such as alumi-
num monostearate and gelatin, which delay absorption. 
Injectable forms are made by forming microencapsule matri-
ces of the drug in biodegradable polymers such as polylac-
tide-polyglycolide, poly( orthoesters) and poly( anhydrides). 
Depending upon the ratio of drug to polymer and the nature 
The compounds can also be formulated as a preparation 
for implantation or injection. Thus, for example, the com-
pounds can be formulated with suitable polymeric or hydro-
25 phobic materials (e.g., as an emulsion in an acceptable oil) 
or ion exchange resins, or as sparingly soluble derivatives 
(e.g., as a sparingly soluble salt). 
of the particular polymer employed, the rate of drug release 30 
The compounds can also be formulated in rectal compo-
sitions (e.g., suppositories or retention enemas containing 
conventional suppository bases such as cocoa butter or other 
glycerides), creams or lotions, or transdermal patches. can be controlled. Injectable formulations are also prepared 
by entrapping the drug in liposomes or microemulsions, 
which are compatible with body tissues. The injectable 
formulations can be sterilized, for example, by filtration 
The presently-disclosed subject matter further includes a 
35 
through a bacterial-retaining filter or by incorporating ster-
kit that can include a compound or pharmaceutical compo-
sition as described herein, packaged together with a device 
useful for administration of the compound or composition. 
As will be recognized by those or ordinary skill in the art, 
ilizing agents in the form of sterile solid compositions which 
can be dissolved or dispersed in sterile water or other sterile 
injectable media just prior to use. Suitable inert carriers can 
include sugars such as lactose. 
the appropriate administration-aiding device will depend on 
the formulation of the compound or composition that is 
selected and/or the desired administration site. For example, 
40 if the formulation of the compound or composition is 
appropriate for injection in a subject, the device could be a 
syringe. For another example, if the desired administration 
site is cell culture media, the device could be a sterile 
Suitable formulations include aqueous and non-aqueous 
sterile injection solutions that can contain antioxidants, 
buffers, bacteriostats, bactericidal antibiotics and solutes 
that render the formulation isotonic with the bodily fluids of 
the intended recipient; and aqueous and non-aqueous sterile 45 
suspensions, which can include suspending agents and 
thickening agents. 
pipette. 
Still further, the presently-disclosed subject matter 
includes a method for treating cancer. In some embodiments 
the method comprises administering a compound, including 
one of the compounds described herein, to a subject in need 
thereof. In some embodied methods a plurality of com-The compositions can take such forms as suspensions, 
solutions or emulsions in oily or aqueous vehicles, and can 
contain formulatory agents such as suspending, stabilizing 
and/or dispersing agents. Alternatively, the active ingredient 
can be in powder form for constitution with a suitable 
vehicle, e.g., sterile pyrogen-free water, before use. 
The formulations can be presented in unit-dose or multi-
dose containers, for example sealed ampoules and vials, and 
can be stored in a frozen or freeze-dried condition requiring 
only the addition of sterile liquid carrier immediately prior 
to use. 
For oral administration, the compositions can take the 
form of, for example, tablets or capsules prepared by a 
conventional technique with pharmaceutically acceptable 
excipients such as binding agents (e.g., pregelatinized maize 
starch, polyvinylpyrrolidone or hydroxypropyl methylcellu-
lose ); fillers (e.g., lactose, microcrystalline cellulose or 
calcium hydrogen phosphate); lubricants (e.g., magnesium 
stearate, talc or silica); disintegrants (e.g., potato starch or 
50 pounds according the present disclosure are administered 
simultaneously or in a predetermined sequence. 
There are also provided processes for the preparation of a 
non-peptide proteasome inhibitor according to the present 
disclosure. For example, in some embodiments, the present 
55 disclosure provides processes for the preparation of a com-
pound of formula (I), pharmaceutically acceptable salt, 
solvate, or physiologically functional derivative thereof. 
Additionally, the present disclosure provides uses of a 
compound of formula (I), a salt, a solvate, or physiological 
60 derivative thereof in the preparation or manufacture of a 
drug and/or medicine, especially a medicine for the treat-
ment of cancer in a mammal. In some embodiments, the 
cancer is a solid cancer. 
Proteasome inhibitors according to the present disclosure 
65 were discovered via a virtual screening and medicinal chem-
istry approach. The compound of the following formula, for 
example, 
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administering to a subject an effective amount of a pharma-
ceutical composition containing at least one compound 
according to formula (I). 
In some embodiments, the present disclosure is directed 
to a pharmaceutical composition comprising at least one 
non-peptide proteasome inhibitor, wherein the proteasome 
inhibitor includes at least one pyrazole. 
In some embodiments, the present disclosure is directed 
to a pharmaceutical composition comprising at least one 
10 
compound according to formula (I). 
In some embodiments, the present disclosure teaches a 
method of synthesizing a non-peptide proteasome inhibitor 
comprising at least one pyrazole. 
In certain embodiments, the subject matter of the present 
disclosure includes a compound of formula (I), a pharma-
15 ceutically acceptable salt, solvate, or physiologically func-
tional derivative thereof. 
Further, the present disclosure provides, in certain 
embodiments, a method of treating a disease in a subject 
comprising the administration of an effective amount of a (also referred to herein as "G4-1"), targets both ~5 and ~5i 
and is highly effectively in suppressing tumor growth in a 
mouse xenograft model of prostate cancer. Furthermore, 
G4-1 is equally effective in killing both parental cells and 
model cell lines with acquired resistance to bortezomib or 
carfilzomib. 
20 pharmaceutical composition containing a non-peptide pro-
tease inhibitor, a pharmaceutically acceptable salt, solvate or 
physiologically functional derivative thereof and pharma-
ceutically acceptable excipient to the subject. 
Following long-standing patent law convention, the terms 
G4-1 was developed by a virtual screen of about 340,000 
small molecules against the chymotrypsin-like (CT-L) activ-
25 "a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a cell" includes a plurality of such cells, and so 
forth. ity conferring subunit of the proteasome followed by in vitro 
screening and subsequent optimization. Unlike carfilzomib 
and bortezomib, which contain linear peptide backbones and 30 
are metabolized rapidly, G4-1 shows excellent in vitro 
metabolic stability. 
Furthermore, G4-1 is highly effective in suppressing 
tumor growth with no apparent toxicity in vivo. In addition, 
the effectiveness of G4-1 as an anticancer agent is not 35 
reduced by prior resistance to bortezomib or carfilzomib. 
Taken together, these results indicate that G4-1 is a meta-
bolically stable proteasome inhibitor with a non-peptide 
scaffold that provides a new therapeutic option for multiple 
myeloma patients refractory to bortezomib or carfilzomib as 40 
well as for patients with solid cancers. 
In some embodiments, the present disclosure provides 
non-peptide proteasome inhibitors that suppress tumor 
growth. 
In some embodiments, the present disclosure provides 45 
methods for treating a subject with solid cancer(s) by 
administering to the subject an effective amount of at least 
one non-peptide proteasome inhibitor. 
In some embodiments, the presently-disclosed subject 
50 
matter provides a non-peptide proteasome inhibitor com-
prising at least one pyrazole. In certain embodiments, the 
present disclosure is directed to reversible non-peptide pro-
teasome inhibitors. 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±20%, in some embodiments 
±10%, in some embodiments ±5%, in some embodiments 
±1 %, in some embodiments ±0.5%, and in some embodi-
ments ±0.1% from the specified amount, as such variations 
are appropriate to perform the disclosed method. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
The presently-disclosed subject matter is further illus-
trated by the following specific but non-limiting examples. 
The following examples may include compilations of data 
that are representative of data gathered at various times 
during the course of development and experimentation 
In some embodiments, the presently-disclosed subject 55 
matter provides a method of inhibiting a proteasome in a 
cell, which involves administering an effective amount of a 
compound of formula (I) to the cell. In some embodiments, 
administering the compound to the cell leads to apoptosis of 
the cell. The cell can be, for example, a cancer cell. 60 related to the present invention. 
In certain embodiments, the present disclosure provides a 
method of treating a disease, wherein the method comprises 
administering to a subject at least one non-peptide protea-
some inhibitor, wherein the non-peptide proteasome inhibi-
tor comprises at least one pyrazole. 
In certain embodiments, the present disclosure provides a 
method of treating a disease, wherein the method comprises 
65 
EXAMPLES 
Virtual Screening 
Structure-based virtual screening was performed follow-
ing a procedure reported previously by the present inven-
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tors. 23 Briefly, the conformation of proteasomes for virtual 
screening was selected from the molecular dynamics trajec-
tory of recently built homology model in complex with 
newly discovered highly potent peptide compounds.24 On 
the basis of favorable binding energy and optimal accom- 5 
modation of the known inhibitors at the active site, the 
protein conformation at 341 ps was selected for the final 
screening. After docking 345 447 compounds included in 
the University of Cincinnati library, 288 compounds for the 
experimental validation were selected based on consensus 10 
scoring, force field based energy scoring functions (MM-
PBSA and MM -GBSA and manual visualization of binding 
modes). Out of 288 compounds tested, 19 compounds were 
found to be active at 5/4M in a CT-L activity assay using the 
IP (more details in the following section). Among these 15 
compounds, G4 was found to potently inhibit the CT-L 
activity of the CP and IP. G4-l, an analogue of G-4, was 
prepared following a synthetic scheme described in FIG. 2D 
and HPLC purification with purity greater than 98%. 
30 
lysates containing 30/4 g of total protein were incubated 
with G4-l (10/4M) in 20S proteasome assay buffer for 30 
min at room temperature. Lysates treated with G4-l were 
subsequently transferred to a semimicrocuvette, and the 
baseline proteasome activity was determined by measuring 
the hydrolysis rate of Suc-LLVY-AMC. After establishment 
of the baseline, lysates treated with G4-l were rapidly mixed 
with the 20S proteasome assay buffer, yielding 25-fold 
dilution. Following this 25-fold dilution from 10 to 0.4/4M 
G4-l, the hydrolysis of Suc-LLVY-AMC was again moni-
tored over approximately 30 min. 
Cell Culture. 
Human cancer cell lines BxPC-3, H358, H-23, LNCaP, 
Pane-l, and RPMI 8226 were obtained from the ATCC 
(American Type Culture Collection) and maintained in the 
ATCC-recommended media, DMEM or RPMI 1640 supple-
mented with 10% fetal bovine serum (from GIBCO, Celi-
Gro, and Atlanta Biologicals). BxPC-3 cells with acquired 
Screening Via In Vitro Proteasome Kinetics. 20 resistance to bortezomib or carfilzomib were established by 
growing them in the presence of stepwise in-creasing con-
centrations of the respective drug over a period of approxi-
mately 6 months. In order to determine the extent of drug 
Compounds were dissolved in DMSO and were used at a 
concentration of 5 f.LM. The stock concentrations of each 
compound were adjusted to make total DMSO percentage 
(v/v) less than 1% in the final reaction solution. 20S human 
immunoproteasomes (IP) and constitutive proteasomes (CP) 25 
purchased from Boston Biochem were diluted to lx assay 
buffer condition (20 mM TrisiC!, pH 8.0, 0.5 mM EDTA, 
0.035% SDS). 1, 2 Compounds were pre-incubated with 50 
ng/well of IP or CP in a 96-well plate at room temperature 
for 90 min. 100 f.LM ofSuc-LLVY-AMC (Sigma) in lx assay 30 
buffer was then added to the wells. Fluorescent signals from 
hydrolyzedAMC (Ex: 360 nm, Em: 460 nm) were recorded 
once per min up to 90 min. The DMSO treated vehicle 
control was used to convert the initial velocities (RFU/min) 
to the percent CT-L activity. The data were collected from 35 
three individually performed experiments, and then the 
mean, standard deviation values were calculated. 
Enzyme Kinetics Assays. 
Initially, purified 20S hnman proteasomes (CP and IP, 
R&D Systems) were used to assess the in vitro inhibition of 40 
proteasome catalytic activities by G4 and its analogs. In the 
96-well format assays involving a 100/4 L total volume, 20S 
proteasomes (0.5/4 g/mL) were incubated with G4, its 
analogs, or reference compounds (e.g., carfilzomib) in assay 
buffer (20 mM Tris-HCI, 0.5 mM EDTA, 0.035% SDS) for 45 
30 min at room temperature. Reactions were initiated by the 
addition of individual subunit-selective fluorogenic sub-
strates containing the AMC (7-amino-4-methylcoumarin) 
group. The following substrates were used: for /31 activity, 
Ac-nLPnLD-AMC (1 00/4M); for /32 and /32i activity, Boc- 50 
LRR-AMC (200/4M); for /35 activity, Ac-WLA-AMC (20/ 
4M); for /3li activity, Ac-PAL-AMC (100/4M); for /35i 
activity, Ac-ANW-AMC (100/4M). The fluorescence of 
liberated AMC was measured over a period of 90 min at 
room temperature using excitation and emission wave- 55 
lengths of 360 and 460 nm on a SpectraMax M5 fluores-
cence plate reader (Molecular Devices). 
In separate experiments, cytosolic extracts ofRPMI-8226 
or BxPC-3 cells were prepared according to the method of 
Kisselev and Goldberg25 and used in place of purified 60 
proteasomes. The fluorescence from liberated AMC of the 
subunit-selective probe substrates was measured as 
described above. 
Jump Dilution Reversibility Assay. 
In further investigation of the mode of proteasome inhi- 65 
bition by G4-l, a dilution assay was performed following a 
procedure previously reported.26 Briefly, RPMI 8226 cell 
resistance, cytotoxicity assays were performed using 
BxPC-3 sublines adapted to 60 nM bortezomib and 200 nM 
carfilzomib, respectively. 
Measurement of Cytotoxic Effects of G4 and its Analogs. 
The cytotoxic effects of G4 and its analogs were deter-
mined using CellTiter Glo assay or CellTiter 96 Aqueous 
One Solution Cell Proliferation assay (Promega). Adherent 
cells (Pane-l, LNCaP, BxPC-3, bortezomib- or carfilzomib-
resistant BxPC-3 sub lines) growing in log phase were plated 
at 7000-10000 cells per well. RPMI 8226 cells growing in 
suspension were collected by centrifugation and plated at 10 
000 cells per well. Twenty-four hours after plating, media 
containing the test compounds were added to each well to 
deliver the intended final concentration. After 72 h, the cell 
viability was determined using the assay protocol recom-
mended by the manufacturers. The resulting signals were 
quantified using a Veritas microplate luminometer or a 
SpectraMax M5 microplate spectrophotometer (Molecular 
Devices). 
Microsomal Stability Assay. 
The metabolic stability profiles of G4-l and reference 
compounds ( carfilzomib and bortezomib) were assessed by 
monitoring the disappearance of the test compounds in the 
presence of liver microsomes. A typical incubation mixture 
(100 sL total volume) for metabolic stability studies con-
tained 1 sM test compounds, 0.5 mg/mL microsomal protein 
(pooled Balb/c mouse liver microsomes prepared in-house 
or BD UltraPool hnman liver microsomes ), 100 mM Tris-
HCI buffer (pH 7.4), and NADPH-generating system (5 mM 
isocitric acid, 0.2 unit/mL isocitric acid dehydrogenase, 5 
mM magnesinm chloride, 1 mM NADP+). After preincuba-
tion at 37° C. for 5 min, the reactions were started by 
addition of NADP+ and further incubated for another 0, 5, 
10, 20 min. For control experiments, NADPH and/or liver 
microsomes were omitted from these incubations. The reac-
tions were terminated by adding 100 sL of ice-cold acetoni-
trile containing phenytoin (1 sM) as internal standard and 
keeping on ice for 30 min, followed by centrifugation at 16 
100 g for 15 min to obtain the supernatant. Aliquots (5 sL) 
were then analyzed for substrate disappearance using liquid 
chromatography-tandem mass spectrometry (Agilent 1200 
HPLC instrument interfaced with Applied Biosystems Qtrap 
3200) equipped with an electrospray ion source. 
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In Vivo Efficacy Assay. 
Six-week-old male BALB/c athymic nude mice (pur-
chased from Orient Bio Inc., SungNam, Republic of Korea) 
were maintained in accordance with the National Institute of 
Toxicological Research of the Korea Food and Drug Admin- 5 
istration guidelines as well as the regulations for the care and 
use of laboratory animals of the animal ethics committee of 
the Konyang University. LNCaP cells (2x106 cells/50 sL) 
were subcutaneously implanted into each animal. After the 
xenograft tumors had grown to a size of '-100 mm3 , mice 10 
(n=5/group) were dosed intraperitoneally twice a week for 4 
weeks with G4-1 (5 mg/kg), carfilzomib (5 mg/kg), or 
vehicle only (8% DMSO in HP-Beta-CD and citrate). Tumor 
volumes (calculated using the following formula, (width?x 
length/2) and body weights were measured every 4 days 15 
during the experimental period. At the end of the experi-
mental period (at day 30), mice were euthanized by cervical 
dislocation and tumors were isolated and weighed. 
Results and Discussion 
Screening of a Small Molecule Library Against the CT-L 20 
Activity of Proteasomes. 
The majority of currently available proteasome inhibitors 
including bortezomib and carfilzomib are small peptides 
with an electrophilic warhead.27 These electro-philic war-
heads such as boronates, epoxyketones, /3-lactones, and 25 
vinyl sulfones directly target the hydroxyl nucleophile of the 
N-terminal threonine in the active site, blocking the pro-
teolytic activity of proteasome via covalent modifications.28 
Although the combination of a peptide backbone with an 
electrophilic pharmacophore can provide a relatively easy 30 
route to proteasomal inhibition, it may suffer from poor 
metabolic stability and side effects. 18•20•29•30 To circumvent 
these concerns, increased efforts have been made recently to 
generate CT-L activity targeting peptide or non-peptide, 
reversible proteasome inhibitors.31 -37 However, no further 35 
development has been made to date, mainly because of low 
proteasome inhibitory potency or poor in vivo efficacy of 
these compounds. 
In the current study, the present inventors employed a 
stepwise screening strategy to identifY non-peptide protea- 40 
some inhibitors lacking reactive warheads with improved 
potency and efficacy against proteasomes (FIG. 2A). Given 
that the CT-L activity-conferring /35 and /35i subunits share 
32 
that described in FIG. 2B (FIG. 3A-B; see below for 
modified synthetic schemes) and measured their potencies 
against the CT-L activity of purified proteasomes. The 
enzyme kinetics studies demonstrated that modifications at 
rings A and B have significant impacts on inhibitory activity, 
G4-1 being one of the most potent inhibitors (FIG. 3D-3F). 
In comparison, modifications at the ring D had little impact 
on the activity of G4. Interestingly, while most of these G4 
derivatives inhibit the CT-L activity of proteasome, some 
such as G4-16 and G4-21 activated the CT-L activity of 
proteasomes, up to 200% at 10 sM (FIG. 3D). The mecha-
nism by which these compounds enhance the CT-L activity 
of proteasome is unclear at this time. While further target 
validation study is needed, the initial studies using these 
G4-1 derivatives showed an apparent correlation between 
the proteasome inhibitory activity and the anticancer effects 
of pyrazole-based G4 analogs, indicating that proteasome 
inhibition is likely to mediate the cytotoxic effects ofG4 and 
G4-1 (FIG. 3G). 
With further reference to FIGS. 3C and 3H, Compounds 
hydrophobic or water-friendly groups at R1 and/or R2 
positions were prepared. Inhibitory activity assay against 
more clinically relevant proteasome catalytic subunit X 
showed that positively charged groups at R1 and R2 posi-
tions are favored for the inhibition of proteasome catalytic 
subunit X. 
The present inventors next further investigated the struc-
ture-activity relationship (SAR) by docking simulation of 
G4-1 to the /35 subunit of the proteasome. The docking 
studies suggest that the improved activity of G4-1 over G-4 
may be attributed to hydrogen bonds created by the intro-
duction of an amide linkage at the ring A (FIG. 4A). Ring B 
is predicted to occupy the S3 sub site located at the interface 
between /35 and /36 subunits. Ring D of G4-1 is predicted 
to occupy the S1 subsite but not as deeply and fully as the 
Leu side chain of bortezomib (FIG. 4B). Overall, G4-1 is 
predicted to occupy only two subsites, as compared to three 
for bortezomib (FIG. 4B), and this predicted difference may 
be exploited to further improve inhibitory potency of G4-1. 
G4-1 as a Lead Proteasome Inhibitor. 
Given its improved inhibitory potency against the CT-L 
activity of purified proteasomes and additional optimization 
potential (due to the amide linkage at the ring A), as 
compared to G4, the present inventors decided to further 
characterize G4-1 as a lead non-peptide proteasome inhibi-
tor. It should be mentioned that although compounds G4-40, 
G4-41, and G4-42 showed the ability to potently inhibit in 
vitro CT-L activity (FIG. 3D), the present inventors found 
that G-40, G4-41, and G4-42 were less potent or noncyto-
a high degree of structural homology at the active sites, 38 the 
present inventors performed a virtual screening of a library 45 
of 345 447 small molecules (provided by University of 
Cincinnati Drug Discovery Center) against the /35i subunit 
following a procedure described by us23 and selected 288 
compounds based on their predicted fit into the active site of 
/35i. 50 toxic in the initial cell viability assays, compared to G4-1 
(FIG. 3F), thus justifYing the selection of G4-1 for further in 
vitro and in vivo studies. The present inventors first tested 
the ability of G4-1 to inhibit the activity of cellular protea-
somes present in cell extracts, other than just purified 
These selected 288 compounds were then tested for their 
ability to inhibit the CT-L activity of proteasomes, and 
subsequently G4 was identified as a lead inhibitor (FIG. 2A). 
Since only a limited amount of G4 was available from the 
library, the present inventors synthesized G4 following the 
scheme described in FIG. 2B. Using this synthetic G4 
compound, the present inventors found that G4 preferen-
tially inhibits the CT-L activity-conferring /31i and /35//35i 
and C-L activity responsible /31 but not /32//32i subunits 
which are responsible for T-L activity (FIG. 2C). Consistent 
with its ability to inhibit the proteasome activity in vitro, G4 
effectively induced cancer cell death in the low micromolar 
range (IC50 ,7 sM) (FIG. 2D). 
Investigation of the G4 Chemical Space. 
To probe structure-activity-relationship of G4 compound, 
the present inventors created a library of G4 analogs modi-
fied at rings A-D following synthetic procedures similar to 
55 proteasomes. As shown in FIG. SA, G4-1 was able to 
effectively inhibit the proteasomal CT-L and C-L activities 
of cell extracts. Similar to G4, G4-1 showed no activity 
against the T-L activity of cell extracts. 
Given that the majority of currently available proteasome 
60 inhibitors, which contain peptide backbones, are prone to 
rapid in vivo inactivation,31 - 33 •36 the present inventors next 
examined whether the pyrazole scaffold-based proteasome 
inhibitor G4-1 is metabolically more stable than those 
peptide-based drugs. Excitingly, G4-1 demonstrated excel-
65 lent metabolic stability profiles in mouse and human liver 
microsomes, as compared to carfilzomib and bortezomib 
(FIG. SB). These results indicate that G4-1 is likely to have 
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much improved in vivo stability compared to carfilzomib 
and bortezomib, which are known to undergo rapid meta-
bolic inactivation.18•21 •40 
Next, the present inventors investigated the mode of 
proteasome inhibition by G4-1 using a jump dilution revers- 5 
ibility assay previously reported. 26 Preincubation of RPMI 
8226 cell extracts with G4-1 for 30 min resulted in a nearly 
complete inhibition of proteasomal activity. However, after 
25-fold dilution, the reaction rate increased exponentially 
with an inhibitor dissociation half-life of approximately 3.2 10 
min (FIG. SC), indicating the reversibility of G4-1/protea-
some interaction. As expected, G4-1 showed a good anti-
cancer activity against a variety of cancer cell lines includ-
ing LNCaP prostate cancer cells (FIG. SD). Interestingly, the 15 
anticancer effect of G4-1 was not negatively impacted by 
acquired resistance to bortezomib or carfilzomib in cell line 
models (FIG. SE), which was generated by continuous drug 
exposure with stepwise increases in concentration (FIG. SF). 
34 
(bs, lH), 7.61 (d, 2H, 1=9.5 Hz), 7.49-7.41 (m, 4H), 7.05 (d, 
lH, 1=10.0 HZ), 6.96 (d, lH, 1=8.0 Hz), 6.90 (s, lH), 2.34 
(s, 3H) 
Compound 3: Benzyl 2-bromoacetate (0.14 mL, 0.909 
mmol) was added to a solution of Compound 2 ( 455 mg, 
1.818 mmol) in NMP (10 mL). The resulting solution was 
heated at about 60-70° C. for 1 hours. The crude product was 
purified by column chromatography on silica gel using 
hexane-ethyl acetate mixture to afford compound 3 as a 
white solid (167 mg, 46%). 1H NMR (CDC13 , 500 MHz) 6 
10.38 (s, lH), 7.44-7.28 (m, llH), 7.039 (d, lH, 1=8.0 Hz), 
6.93 (d, lH, 1=8.0 Hz), 6.70 (s, lH), 5.18 (s, 2H), 4.92 (s, 
2H), 2.31 (s, 3H) 
Compound 4: Lithium aluminum hydride (29 mg, 0.764 
mmol) was added to a solution of Compound 3 (100 mg, 
0.251 mmol) in anhydrous THF (10 mL). The mixture was 
stirred at room temperature under nitrogen atmosphere for 2 
h. After that period the mixture was carefully poured into ice 
water (30 mL) and acidified with 1M HCl at pH 2-3. The 
In Vivo Anticancer Activity of G4-1. 20 crude product was extracted by ethyl acetate (3x30 mL), 
dried over anhydrous sodium sulfate. The solvent was 
evaporated and purified by column chromatography on silica 
gel using hexane-ethyl acetate mixture to afford compound 
Lastly, the Present Inventors Investigated the in vivo 
anticancer efficacy of G4-1 using a xenograft mouse model. 
Given that one of important goals in the area of proteasome 
inhibitor therapy is to expand therapeutic benefits to patients 
with solid cancers, the present inventors used a solid cancer 25 
xenograft model of human prostate LNCaP cancer cell line 
following a procedure the present inventors previously 
reported. 6 As shown in FIG. 6A-C, G4-1 effectively sup-
pressed tumor growth in vivo without apparent systemic 
toxicity in mice (for images of mice treated with G4-1, see 30 
FIG. 6E). Unlike mice treated with carfilzomib which 
resulted in weight loss, mice treated with G4-1 maintained 
normal weight gain over the course of treatment (FIG. 6D). 
4 as a white solid (60mg, 80%).1HNMR (CDC13 , 500 MHz) 
610.48 (s, lH), 7-53-7.42 (m, 5H), 7.38 (s, lH), 7.039 (d, 
lH, 1=8.0 Hz), 6.939 (d, lH, 1 =8.0 Hz), 6.68 (s, lH), 
4.32-4.24 (m, 2H), 4.09-4.08 (m, 2H), 2.33 (s, 3H), 1.89 (bs, 
lH) 
Compound 5: Triethylamine (0.014 mL, 0.102 mmol) was 
added to a solution of compound 4 (20 mg, 0.068 mmol) and 
4-Toluensulfonyl chloride (14 mg, 0.075 mmol) in dichlo-
romethane (1 mL ). The resulting solution was stirred at rt for 
overnight. The reaction mixture was concentrated under 
reduced pressure. The crude product was purified by column 
Conclusions 35 chromatography on silica gel using hexane-ethyl acetate 
mixture to afford compound 5 as a white solid (13 mg, 43% ). 
1H NMR (CDC13 , 500 MHz) 610.02 (s, lH), 7.52-7.45 (m, 
7H), 7.31 (s, lH), 7.06-7.03 (m, 3H), 6.89 (d, lH, 1=8.0 Hz), 
The present inventors have successfully developed a 
group of non-peptide, reversible proteasome inhibitors, 
including G4-1. This inhibitor utilizes a pyrazole scaffold 
and does not rely on an electrophilic warhead to mediate 
proteasome inhibition. In addition to its novel scaffold, G4-1 40 
represents an important advance due to its effectiveness in 
models of proteasome inhibitor resistance and metabolic 
stability. This is notable, as MM patients who are initially 
responsive to currently FDA-approved proteasome inhibi-
tors almost inevitably develop resistance to those drugs. 45 
Therefore, G4-1 provides an opportunity for an additional 
option for these refractory MM patients. Multiple clinical 
trials clearly demonstrated that the clinically approved pro-
teasome inhibitors carfilzomib and bortezomib lack utility in 
the treatment of solid tumors due to their rapid metabolism, 50 
irreversible inhibition, sensitivity to resistance, and dose-
limiting toxic-ities. 18•20 •22 •41 •42 
Synthesis of Compounds 
Synthesis of G4. 
G4 was synthesized following a procedure described 55 
below and set forth in FIG. 2B. 
Compound 2: Hydrazine (0.15 mL, 4.713 mmol) was 
added to a solution of 1-(2-Hydroxy-5-methylphenyl)-3-
phenyl-1, 3-propanedione (1 g, 3.928 mmol) in ethanol (10 
mL). The mixture was refluxed with stirring for 1 h. The 60 
mixture was cooled to room temperature. The solvent was 
evaporated to dryness. The formed precipitate was taken in 
ethyl acetate (30 mL), washed with brine (3x30 mL), and 
dried over anhydrous sodium sulfate. The solvent was 
evaporated and the solid residue was recrystallized from hot 65 
ethanol. Compound 2 was obtained as yellow solid (955 mg, 
97%). 1H NMR (CDC13 , 500 MHz) 6 10.62 (bs, lH), 10.34 
6.53 (s, lH), 4.43 (t, 2H, 1=5.0 Hz), 4.29 (t, 2H, 1=5.0 Hz), 
2.33 (s, 3H), 2.07 (s, 3H) 
Compound 6: Triethylamine (0.008 mL, 0.06 mmol) was 
added to a solution of compound 5 (9 mg, 0.02 mmol) and 
3-(Trifluoromethyl)benzenesulfonyl chloride (0.006 ml, 
0.04 mmol) in dichloromethane (1 mL). The resulting solu-
tion was stirred at rt for 6 h. The reaction mixture was 
concentrated under reduced pressure. The crude product was 
purified by column chromatography on silica gel using 
hexane-ethyl acetate mixture to afford compound 6 as a 
white solid (12 mg, 91%). 1H NMR (CDC13 , 500 MHz) 
67.86 (s, lH), 7.737 (d, 2H, 1=8.0 Hz), 7.57 (d, 2H, 1=8.5), 
7.49-7.36 (m, 7H) 7.29 (d, lH, 1=8.5 Hz), 7.187.14 (m, 3H), 
6.55 (s, lH), 4.42 (t, 2H, 1=5.5 Hz), 4.24 (t, 2H, 1=5.5 Hz), 
2.36 (s, 3H), 2.26 (s, 3H) 
Compound 7: (R)-(+)-1-Boc-3-aminopyrrolidine (7 mg, 
0.0364 mmol) was added to a solution of compound 6 (12 
mg, 0.0182 mmol) and potassium carbonate (0.005 mg, 
0.0364 mmol) in DMF (0.5 mL). The resulting solution was 
stirred at rt for 2 h. The reaction mixture was concentrated 
under reduced pressure. The crude product was purified by 
column chromatography on silica gel using hexane-ethyl 
acetate mixture to afford compound 7 as a white solid (8 mg, 
66%). 1H NMR (CDC13 , 500 MHz) 67.92 (s, lH), 7.78-7.76 
(m, 2H), 7.57-7.41 (m, 7H), 7.23 (m, lH), 7.13-7.11 (m, 
lH), 6.58 (s, lH) 4.17 (m, 2H), 3.89 (m, lH), 3.64-3.22 (m, 
6H), 3.03 (m, 2H), 2.37 (s, 3H) 
G4: Trifluoroacetic acid (0.5 mL) was added to a solution 
of Compound 7 (8 mg, 0.0119 mmol) in dichloromethane (1 
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mL). The resulting solution was stirred at rt for 1 h. The 
reaction mixture was concentrated under reduced pressure. 
The crude product was purified by colunm chromatography 
on silica gel using dichloromethane-methanol mixture to 
afford G4 as a semi solid (5 mg, 73%). 1H NMR (CDC13 , 5 
500 MHz) 610.69 (bs, lH), 10.11 (bs, lH), 7.96-7.78 (m, 
3H), 7.59-7.35 (m, 7H), 7.13-7.09 (m, 2H), 6.96 (d, lH, 
J=8.5 Hz), 6.45 (s, lH), 4.60 (m, 2H), 4.23 (m, lH), 3.85 (m, 
2H), 3.61 (m, 4), 2.37 (m, 5H), [a]d"=+l.2 (c=0.14, CHC13 ) 10 
Synthesis of G4-1. 
G4-1 was synthesized by the following procedure, which 
is further described below. 
0 0 OH 
2 
Hydrazine • EtOH 
Reflux • 1 h 
0 
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Compound 8: Triethylamine (0.02 mL, 0.139 mmol) was 
50 added to a solution of compound 3 (37 mg, 0.0928 mmol) 
and 3-(Trifluoromethyl)benzenesulfonyl chloride (0.016 
mL, 0.102 mmol) in dichloromethane (1 mL). The resulting 
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solution was stirred at rt for 1 h. The reaction mixture was 
concentrated under reduced pressure. The crude product was 
purified by colunm chromatography on silica gel using 
hexane-ethyl acetate mixture to afford compound 8 as a 
white solid (50 mg, 89%). lH NMR (CDC13 , 500 MHz) 
67.89 (s, lH), 7.72 d, 2H, 1=7.0 Hz), 7.56 (s, lH), 7.46-7.32 
(m, 12H), 7.15 (d, lH, J=8.0 Hz), 6.62 (s, lH), 5.20 (s, 2H), 
4.85 (s, 2H), 2.34 (s, 3H) 
Compound 9: To a solution of compound 8 (40 mg, 
0.0659 mmol) in methanol (2 mL) was added 10% Pd!C (10 
mg) and the reaction vessel purged with H2 gas. The reaction 
mixture was stirred under H2 atmosphere (H2 balloon) for 
0.5 h. Excess H2 was displaced by air and the catalyst was 
removed by filtration through Celite. The filtrate was con-
centrated under reduced pressure. Compound 9 as a semi 
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solid (34 mg, 99%). 1H NMR (CDC13 , 500 MHz) 6 9.22 (bs, 
lH), 7.81 (s, lH), 7.71-7.67 (m, 2H), 7.477.33 (m, 8H), 7.16 
(d, lH, J=8.0 Hz), 6.48 (s, lH), 4.87 (s, 2H), 2.27 (s, 3H) 
Compound 10: N,N-Diisopropylethylamine (0.057 ml, 
0.33 mmol) was added to a solution of compound 9 (24 mg, 5 
0.0658 mmol), (R)-( + )-1-Boc-3-aminopyrrolidine (12 mg, 0 
0658 mmol), and 0-(benzotriazol-1-yl)-N,N,N',N'-tetram-
ethyluronium tetrafluorobotate (32 mg, 0.099 mmol) in 
dichloromethane (2 mL). The resulting solution was stirred 
at rt for 2 h. The reaction mixture was concentrated under 10 
38 
6.71 (s, lH), 6.65 (s, lH), 4.77 (s, 2H), 3.71-3.68 (m, lH), 
3.47-3.37 (m, 4H), 3.15-3.13 (m, lH), 2.45-2.43 (m, 2H), 
2.38 (s, 3H), 2.372.35 (m, 4H) 
G4-8: 1H NMR (CDC13 , 500 MHz) 67.92 (s, lH), 7.86-
7.79 (m, 2H), 7.62 (s, lH), 7.55 (t, lH, 1=7.5 Hz), 7.46-7.41 
(m, 5H), 7.13-7.05 (m, 2H), 6.91 (s, lH), 6.61 (s, lH), 4.74 
(s, 2), 3.69-3.62 (m, lH), 3.34-3.26 (m, 5H), 2.36-2.31 (m, 
5H), 2.04-1.95 (m, 2H), 1.73-1.70 (m, 2H); MS (MALDI-
TOF): MH+, Calcd. for C32H32F3 N4 0 5 S 641.2. found 642.2. 
G4-9: 1H NMR (CDC13 , 500 MHz) 67.85-7.83 (m, lH), 
7.74-7.67 (m, 2H), 7.54 (s, lH), 7.48-7.23 (m, 12H), 7.12-
7.08 (m, 2H), 6.94-6.89 (m, lH), 6.76 (m, lH), 6.58-6.49 
(m, 2H), 5.16-5.14 (m, lH), 4.82 (s, 2H), 3.63-3.53 (m, 2H), 
reduced pressure. The crude product was purified by column 
chromatography on silica gel using hexane-ethyl acetate 
mixture to afford compound 10 as a white solid ( 40 mg, 
89%). 1H NMR (CDC13 , 500 MHz) 67.99 (s, lH), 7.88-7.84 
(m, 2H), 7.58-7.37 (m, 7H), 7.24 (d, lH, J=8.0 Hz), 6.97-
6.90 (m, lH), 6.72 (s, lH), 6.42 (m, lH), 4.80 (s, 2H), 
4.45-4.43 (m, lH), 3.63-3.59 (m, lH), 3.35-3.31 (m, 2H), 
3.04 (m, lH), 2.39 (s, 3H), 2.12-2.09 (m, lH), 1.76 (m, 
1H)1.37 (s, 9H) 
15 2.98-2.93 (m, 3H), 2.33-2.27 (m, 6H), 2.17-2.12 (m, 2H); 
MS (MALDI-TOF): MH+, Calcd. for C42H38F3 N30 5 S, 
586.2. found 754.2. 
G4-10: 1H NMR (CDC13 , 500 MHz) 6 7.87 (s, lH), 
7.75-7.71 (m, 2H), 7.61 (s, lH), 7.55-7.34 (m, 7H), 7.15 (d, 
G4-1: Trifluoroacetic acid (0.5 mL) was added to a 
solution of compound 10 (20 mg, 0.0292 mmol) in dichlo-
romethane (1 mL ). The resulting solution was stirred at rt for 
0.5 h. The reaction mixture was concentrated under reduced 
pressure. The crude product was purified by column chro-
matography on silica gel using dichloromethane-methanol 
mixture to afford G4-1 as a semi solid (12 mg, 70%). G4-1 
was further purified by HPLC to yield G4-1 with purity 
greater than 98.5%. 1H NMR (CDC13 , 500 MHz) 69.22 (bs, 
lH), 9.01 (bs, lH), 8.00 (s, lH), 7.88-7.81 (m, 3H), 7.57-
7.39 (m, 7H), 7.13 (d, lH, J=8.0 Hz), 7.11 (d, lH, J=8.0 Hz), 
6.55 (s, lH), 4.81 (s, 2H), 4.51 (m, lH), 3.48-3.29 (m, 4H), 
2.34-2.27 (m, 4H), 2.05 (m, lH); MS (ESI): M+W, 
C29H28F3 N4 0 4 S, Calcd. 585.1778. found 585.1779. 
[aL;s=-11.5 (C=0.23, CHC13 ) 
20 lH, J=8.5 Hz), 6.59 (s, lH), 5.33-5.30 (m, lH), 4.84 (s, 2H), 
4.66 (d, 2H, 1=7.5 Hz), 2.34 (s, 3H), 1.76 (s, 3H), 1.70 (s, 
3H); MS (MALDI-TOF): MK+, Calcd. for 
C30H30F3KN30 4 S. 623.2. found 623.2. 
G4-11: 1H NMR (CDC13 , 500 MHz) 6 7.86 (s, lH), 
25 7.74-7.70 (m, 2H), 7.53 (s, lH), 7.49-7.32 (m, 7H), 7.16 (d, 
lH, J=8.5 Hz), 6.59 (s, lH), 6.32 (s, lH), 5.96 (s, lH), 5.10 
(s, 2H), 4.79 (s, 2H), 2.34 (s, 3H), 2.30 (s, 3H) 
G4-12: 1H NMR (CDC13 , 500 MHz) 6 8.73 (s, lH), 7.88 
(s, lH), 7.76-7.71 (m, 2H), 7.52 (s, lH), 7.49-7.26 (m, 7H), 
30 7.16 (d, lH, J=8.0 Hz), 6.61 (s, lH), 5.33 (s, 2H), 4.81 (s, 
2H), 2.47 (s, 3H), 2.35 (s, 3H) 
G4-1 derivatives were synthesized following a procedure 
used for the synthesis of G4-1 with exception of using 
different starting materials. Representative mnr and mass 
data for some G4-1 derivatives (G4-2-G4-13) are provided 
below. 
G4-13: 1H NMR (CDC13 , 500 MHz) 6 7.87 (s, lH), 
7.76-7.72 (m, 2H), 7.54 (s, lH), 7.49-7.32 (m, 7H), 7.15 (d, 
lH, J=8.0 Hz), 6.60 (s, lH), 5.95 (s, lH), 5.21 (s, 2HO, 4.87 
35 (s, 2H), 2.41 (s, 3H), 2.35 (s, 3H) 
G4-2: 1H NMR (CDC13 , 500 MHz) 67.83 (s, lH), 7.74 (d, 40 
2H, 1=7.5 Hz), 7.46-7.15 (m, 9H), 6.51 (s, lH), 4.83 (s, 2H), 
2.31 (s, 3H) 
G4-3: 1H NMR (CDC13 , 500 MHz) 67.84 (s, lH), 7.75-
7.71 (m, 2), 7.53-7.41 (m, 7H), 7.44 (d, lH, J =8.0 Hz), 7.12 
(d, lH, J=8.0 Hz), 6.57 (s, lH), 4.85 (s, 2H), 3.02 (s, 3H), 45 
3.00 (s, 3H), 2.32 (s, 3H)); MS (MALDI-TOF): MW, Calcd. 
for C27H25F3 N30 4 S 544.1. found 544.1. 
G4-4: 1H NMR (CDC13 , 500 MHz) 67.96 (s, lH), 7.85-
7.80 (m, 2H), 7.61 (s, lH), 7.54-7.38 (m, 6H), 7.13-7.10 (m, 
2H), 6.73 (s, lH), 6.44 (m, lH), 4.78 (s, 2H), 3.08 (d, 2H, 50 
J=8.5 Hz), 2.37 (s, 3H), 0.82 (s, 3H); MS (MALDI-TOF): 
MH+, Calcd. 586.2 for C30H31F3N30 4 S. found 586.2. 
G4-5: 1H NMR (CDC13 , 500 MHz) 67.98 (s, lH), 7.87-
7.82 (m, 2H), 7.59-7.46 (m, 5H), 7.99 (d, 2H, J=8.0 Hz), 
7.12 (d, lH, 1=7.5 Hz), 7.03 (d, lH, 1=7.5 Hz), 6.70 (s, lH), 55 
6.39 (s, lH), 4.72 (s, 2H), 3.54 (s, 2H), 2.38 (s, 3H), 1.25 (s, 
6); MS (MALDI-TOF): MH+, Calcd. for C29H29F3N3 0 5 S 
588.2. found 588.2. 
G4-6: 1H NMR (CDC13 , 500 MHz) 67.94 (s, lH), 7.84-
7.78 (m, 2H), 7.63 (s, lH), 7.52-7.37 (m, 6H), 7.20-7.14 (m, 60 
2H), 6.61 (m, 2H), 4.73 (s, 2H), 3.97-3.92 (m, lH), 3.75-
3.64 (m, 2H), 3.54-3.50 (m, lH), 3.29-3.26 (m, lH), 2.38 (s, 
3H), 1.95-1.78 (m, 3H), 1.53-1.47 (m, lH); MS (MALDI-
TOF): MH+, Calcd. for 600.2. found 600.2. 
G4-7: 1H NMR (CDC13 , 500 MHz) 67.97 (s, lH), 7.86- 65 
7.82 (m, 2H), 7.62 (s, lH), 7.57-7.47 (m, 4H), 7.39 (d, 2H, 
J=8.0 Hz), 7.14 (d, lH, J=8.0 Hz), 7.08 (d, lH, J=8.0 Hz), 
Throughout this document, various references are men-
tioned. All such references are incorporated herein by ref-
erence, including the references set forth in the following 
list: 
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1. A compound of the formula: 
or a pharmaceutically-acceptable salt thereof, wherein 
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3, The compound of claim 2, wherein R2 is selected from 
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6. The compound of claim 2, wherein R2 is 
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13. The compound of claim 1, according to the formula 
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15. A pharmaceutical composition, comprising: the com-
pound of claim 1, and a pharmaceutically-acceptable carrier. 
16. A method of inhibiting a 26S proteasome in a cell, 
20 comprising administering an effective amount of the com-
pound of claim 1 to the cell. 
17. The method of claim 16, wherein the administering 
the compound to the cell leads to apoptosis of the cell. 
18. The method of claim 16, wherein the cell is a cancer 
25 cell. 
19. A method of treating a 26S proteasome-mediated 
disease in a subject comprising administering an effective 
amount of a pharmaceutical composition containing the 
compound of claim 1 to the subject. 
30 20. Themethodofclaim 19, wherein the subject is in need 
of treatment for cancer. 
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